Literature DB >> 9520289

Rapid blood clearance of mouse IgG2a and human IgG1 in many nude and nu/+ mouse strains is due to low IgG2a serum concentrations.

N Reddy1, G L Ong, T M Behr, R M Sharkey, D M Goldenberg, M J Mattes.   

Abstract

We reported previously that the blood clearance of injected mouse IgG2a was extremely rapid in many strains of nude and nu/+ mice. In an attempt to determine the cause of this phenomenon, the levels of endogenous IgG2a in the blood of these mice was assayed. It was found that the serum level of IgG2a was extremely low in many of these mice, below 50 microg/ml, which is 20-100 times lower than the expected normal value. Great heterogeneity between individual mice was observed in their blood level of IgG2a, and there was an excellent correlation between low blood IgG2a levels and rapid clearance of injected IgG2a. Thus, the blood IgG2a levels are so low that a novel, previously undescribed effect occurs, namely the rapid clearance of small amounts of injected IgG2a. The clearance is due primarily to binding sites in the spleen and liver. The low level of endogenous IgG2a is not due to the lack of a thymus, since it occurs in nu/+ as well as nude mice, but can probably be attributed to the very clean environment in which these mice are raised. In assays of sera from approximately 50 mouse strains, low IgG2a levels were found in all nude colonies and also in some normal mouse strains. Some nude mice displayed relatively normal IgG2a clearance rates despite having low levels of endogenous IgG2a. In repeated bleedings of individual mice, IgG2a levels were found to fluctuate greatly. A similar clearance effect was observed with a human IgG1 Ab injected into mice. This rapid clearance of injected IgG, of certain subclasses, represents a practical problem for many experiments in which antibodies are used for diagnosis or therapy, and several methods of circumventing the problem are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9520289     DOI: 10.1007/s002620050456

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  16 in total

1.  Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.

Authors:  Jürgen Grünberg; Dennis Lindenblatt; Holger Dorrer; Susan Cohrs; Konstantin Zhernosekov; Ulli Köster; Andreas Türler; Eliane Fischer; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-24       Impact factor: 9.236

2.  Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.

Authors:  Oskar Vilhelmsson-Timmermand; Elmer Santos; Daniel L J Thorek; Susan Evans-Axelsson; Anders Bjartell; Hans Lilja; Steven M Larson; Sven-Erik Strand; Thuy A Tran; David Ulmert
Journal:  Nucl Med Biol       Date:  2014-12-23       Impact factor: 2.408

3.  Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.

Authors:  Anastasia Pantelias; John M Pagel; Nathan Hedin; Laura Saganic; Shani Wilbur; Donald K Hamlin; D Scott Wilbur; Yukang Lin; Diane Stone; Don Axworthy; Ajay K Gopal; Oliver W Press
Journal:  Blood       Date:  2007-02-15       Impact factor: 22.113

4.  Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.

Authors:  Robert M Sharkey; Habibe Karacay; David M Goldenberg
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

5.  Passive Immunization with a Single Monoclonal Neutralizing Antibody Protects against Cutaneous and Mucosal Mouse Papillomavirus Infections.

Authors:  Sarah A Brendle; Jingwei Li; Nancy M Cladel; Karla K Balogh; Jennifer Booth; Debra A Shearer; Vonn Walter; Song Lu; Neil D Christensen; Danielle Covington; Jake DeBroff; Janice Milici; Yusheng Zhu; Raphael Viscidi; Jiafen Hu
Journal:  J Virol       Date:  2022-08-03       Impact factor: 6.549

6.  Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.

Authors:  Cornelius Cilliers; Bruna Menezes; Ian Nessler; Jennifer Linderman; Greg M Thurber
Journal:  Cancer Res       Date:  2017-12-07       Impact factor: 12.701

7.  Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.

Authors:  Ajay K Gopal; Oliver W Press; Shani M Wilbur; David G Maloney; John M Pagel
Journal:  Blood       Date:  2008-05-23       Impact factor: 22.113

8.  Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma.

Authors:  Urs B Hagemann; Dessislava Mihaylova; Steinar R Uran; Joergen Borrebaek; Derek Grant; Roger M Bjerke; Jenny Karlsson; Alan S Cuthbertson
Journal:  Oncotarget       Date:  2017-04-07

9.  Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance.

Authors:  Chisato M Yamazaki; Aiko Yamaguchi; Yasuaki Anami; Wei Xiong; Yoshihiro Otani; Jangsoon Lee; Naoto T Ueno; Ningyan Zhang; Zhiqiang An; Kyoji Tsuchikama
Journal:  Nat Commun       Date:  2021-06-10       Impact factor: 14.919

10.  LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.

Authors:  Yasuaki Anami; Mi Deng; Xun Gui; Aiko Yamaguchi; Chisato M Yamazaki; Ningyan Zhang; Cheng Cheng Zhang; Zhiqiang An; Kyoji Tsuchikama
Journal:  Mol Cancer Ther       Date:  2020-09-02       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.